Menu Search
Equities

Aytu Biopharma Inc

AY20:STU

Aytu Biopharma Inc

Actions
  • Price (EUR)2.10
  • Today's Change-0.08 / -3.67%
  • Shares traded0.00
  • 1 Year change+43.84%
  • Beta--
Data delayed at least 15 minutes, as of Sep 19 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Aytu Biopharma Inc grew revenues 11.10% from 96.67m to 107.40m while net income improved from a loss of 108.78m to a smaller loss of 17.05m.
Gross margin65.32%
Net profit margin-14.60%
Operating margin-1.53%
Return on assets-9.91%
Return on equity-38.18%
Return on investment-25.58%
More ▼

Cash flow in USDView more

In 2023, Aytu Biopharma Inc increased its cash reserves by 18.72%, or 3.63m. Cash Flow from Financing totalled 8.87m or 8.26% of revenues. In addition the company used 5.13m for operations while cash used for investing totalled 117.00k.
Cash flow per share-1.02
Price/Cash flow per share--
Book value per share5.53
Tangible book value per share-4.19
More ▼

Balance sheet in USDView more

Aytu Biopharma Inc has a Debt to Total Capital ratio of 35.20%, a higher figure than the previous year's 27.83%.
Current ratio0.8499
Quick ratio0.6923
Total debt/total equity0.5431
Total debt/total capital0.352
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.